Welcome to LookChem.com Sign In|Join Free

Cas Database

422560-40-5

422560-40-5

Identification

  • Product Name:Benzeneethanimidamide,4-bromo-N-hydroxy-

  • CAS Number: 422560-40-5

  • EINECS:

  • Molecular Weight:229.076

  • Molecular Formula: C8H9 Br N2 O

  • HS Code:2925290090

  • Mol File:422560-40-5.mol

Synonyms:N-Hydroxy-2-(4-bromophenyl)acetamidine

Post Buying Request Now
Entrust LookChem procurement to find high-quality suppliers faster

Safety information and MSDS view more

  • Signal Word:Warning

  • Hazard Statement:H302 Harmful if swallowedH312 Harmful in contact with skin H315 Causes skin irritation H319 Causes serious eye irritation H332 Harmful if inhaled H335 May cause respiratory irritation

  • First-aid measures: General adviceConsult a physician. Show this safety data sheet to the doctor in attendance.If inhaled If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician. In case of skin contact Wash off with soap and plenty of water. Consult a physician. In case of eye contact Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician. If swallowed Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.

  • Fire-fighting measures: Suitable extinguishing media Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. Wear self-contained breathing apparatus for firefighting if necessary.

  • Accidental release measures: Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust. For personal protection see section 8. Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the environment must be avoided. Pick up and arrange disposal. Sweep up and shovel. Keep in suitable, closed containers for disposal.

  • Handling and storage: Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Avoid exposure - obtain special instructions before use.Provide appropriate exhaust ventilation at places where dust is formed. For precautions see section 2.2. Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

  • Exposure controls/personal protection:Occupational Exposure limit valuesBiological limit values Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of workday. Eye/face protection Safety glasses with side-shields conforming to EN166. Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU). Skin protection Wear impervious clothing. The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace. Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique(without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands. The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the standard EN 374 derived from it. Respiratory protection Wear dust mask when handling large quantities. Thermal hazards

Supplier and reference price

  • Manufacture/Brand
  • Product Description
  • Packaging
  • Price
  • Delivery
  • Purchase
  • Manufacture/Brand:SynQuest Laboratories
  • Product Description:2-(4-Bromophenyl)-N-hydroxyethanimidamide
  • Packaging:1 g
  • Price:$ 168
  • Delivery:In stock
  • Buy Now
  • Manufacture/Brand:Matrix Scientific
  • Product Description:2-(4-Bromophenyl)acetamidoxime 95+%
  • Packaging:1g
  • Price:$ 246
  • Delivery:In stock
  • Buy Now
  • Manufacture/Brand:Labseeker
  • Product Description:BENZENEETHANIMIDAMIDE,4-BROMO-N-HYDROXY- 95
  • Packaging:50g
  • Price:$ 3025
  • Delivery:In stock
  • Buy Now
  • Manufacture/Brand:Crysdot
  • Product Description:2-(4-Bromophenyl)-N-hydroxyacetimidamide 97%
  • Packaging:10g
  • Price:$ 363
  • Delivery:In stock
  • Buy Now
  • Manufacture/Brand:ChemScene
  • Product Description:2-(4-Bromophenyl)-N-hydroxyacetimidamide
  • Packaging:1g
  • Price:$ 116
  • Delivery:In stock
  • Buy Now
  • Manufacture/Brand:ChemScene
  • Product Description:2-(4-Bromophenyl)-N-hydroxyacetimidamide
  • Packaging:5g
  • Price:$ 349
  • Delivery:In stock
  • Buy Now
  • Manufacture/Brand:Biosynth Carbosynth
  • Product Description:2-(4-Bromophenyl)-1-(hydroxyimino)ethylamine
  • Packaging:5 g
  • Price:$ 578
  • Delivery:In stock
  • Buy Now
  • Manufacture/Brand:Biosynth Carbosynth
  • Product Description:2-(4-Bromophenyl)-1-(hydroxyimino)ethylamine
  • Packaging:2 g
  • Price:$ 272
  • Delivery:In stock
  • Buy Now
  • Manufacture/Brand:Biosynth Carbosynth
  • Product Description:2-(4-Bromophenyl)-1-(hydroxyimino)ethylamine
  • Packaging:500 mg
  • Price:$ 90
  • Delivery:In stock
  • Buy Now
  • Manufacture/Brand:Biosynth Carbosynth
  • Product Description:2-(4-Bromophenyl)-1-(hydroxyimino)ethylamine
  • Packaging:250 mg
  • Price:$ 52.5
  • Delivery:In stock
  • Buy Now

Relevant articles and documentsAll total 10 Articles be found

Novel O-acylated amidoximes and substituted 1,2,4-oxadiazoles synthesised from (+)-ketopinic acid possessing potent virus-inhibiting activity against phylogenetically distinct influenza A viruses

Chernyshov, Vladimir V.,Yarovaya, Olga I.,Esaulkova, Iana L.,Sinegubova, Ekaterina,Borisevich, Sophia S.,Popadyuk, Irina I.,Zarubaev, Vladimir V.,Salakhutdinov, Nariman F.

, (2021/12/16)

This article describes the synthesis and antiviral activity evaluation of new substituted 1,2,4-oxadiazoles containing a bicyclic substituent at position 5 of the heterocycle and O-acylated amidoximes as precursors for their synthesis. New compounds were

NOVEL HETEROARYL COMPOUND, ENANTIOMER, DIASTEREOMER OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND ANTIVIRAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT

-

Paragraph 0850, (2020/02/14)

The present invention relates to a novel heteroaryl compound, an enantiomer, a diastereomer or a pharmaceutically acceptable salt thereof, and an antiviral composition comprising the same as an active ingredient. The novel compounds represented by formula (I) or formula (II) according to the present invention are remarkably superior in antiviral activity against an influenza virus, and furthermore, have low cytotoxicity and thus low adverse effects on a human body. Therefore, a pharmaceutical composition containing the same as an active ingredient can be effectively used for the prevention or treatment of diseases caused by an influenza virus infection.

Nitrobenzofurazan derivatives of N′-hydroxyamidines as potent inhibitors of indoleamine-2,3-dioxygenase 1

Paul, Saurav,Roy, Ashalata,Deka, Suman Jyoti,Panda, Subhankar,Trivedi, Vishal,Manna, Debasis

, p. 364 - 375 (2016/06/13)

Tryptophan metabolism through the kynurenine pathway is considered as a crucial mechanism in immune tolerance. Indoleamine 2,3-dioxygenase 1 (IDO1) plays a key role in tryptophan catabolism in the immune system and it is also considered as an important therapeutic target for the treatment of cancer and other diseases that are linked with kynurenine pathway. In this study, a series of nitrobenzofurazan derivatives of N′-hydroxybenzimidamides (1) and N′-hydroxy-2-phenylacetimidamides (2) were synthesized and their inhibitory activities against human IDO1 enzyme were tested using in-vitro and cellular enzyme activity assay. The optimization leads to the identification of potent compounds, 1d, 2i and 2k (IC50 = 39-80 nM), which are either competitive or uncompetitive inhibitors of IDO1 enzyme. These compounds also showed IDO1 inhibition potencies in the nanomolar range (IC50 = 50-71 nM) in MDA-MB-231 cells with no/negligible amount of cytotoxicity. The stronger selectivity of the potent compounds for IDO1 enzyme over tryptophan 2,3-dioxygenase (TDO) enzyme (312-1593-fold) also makes them very attractive for further immunotherapeutic applications.

Synthesis, SAR, and series evolution of novel oxadiazole-containing 5-lipoxygenase activating protein inhibitors: Discovery of 2-[4-(3-{(R)-1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]- N, N -dimethyl-acetamide (BI 665915)

Takahashi, Hidenori,Riether, Doris,Bartolozzi, Alessandra,Bosanac, Todd,Berger, Valentina,Binetti, Ralph,Broadwater, John,Chen, Zhidong,Crux, Rebecca,De Lombaert, Stéphane,Dave, Rajvee,Dines, Jonathon A.,Fadra-Khan, Tazmeen,Flegg, Adam,Garrigou, Michael,Hao, Ming-Hong,Huber, John,Hutzler, J. Matthew,Kerr, Steven,Kotey, Adrian,Liu, Weimin,Lo, Ho Yin,Loke, Pui Leng,Mahaney, Paige E.,Morwick, Tina M.,Napier, Spencer,Olague, Alan,Pack, Edward,Padyana, Anil K.,Thomson, David S.,Tye, Heather,Wu, Lifen,Zindell, Renee M.,Abeywardane, Asitha,Simpson, Thomas

, p. 1669 - 1690 (2015/04/21)

The synthesis, structure-activity relationship (SAR), and evolution of a novel series of oxadiazole-containing 5-lipoxygenase-activating protein (FLAP) inhibitors are described. The use of structure-guided drug design techniques provided compounds that demonstrated excellent FLAP binding potency (IC50 4 synthesis in human whole blood (IC50 4 production.

DUAL-ACTING ANTIHYPERTENSIVE AGENTS

-

Page/Page column 51-52, (2010/02/17)

In one aspect, the invention relates to compounds having the formula: wherein: Ar, r, Z, X, R3, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

Process route upstream and downstream products

Process route

4-Bromophenylacetonitrile
16532-79-9

4-Bromophenylacetonitrile

(z)-2-(4-bromophenyl)-N′-hydroxyacetimidamide
1433999-78-0,422560-40-5

(z)-2-(4-bromophenyl)-N′-hydroxyacetimidamide

Conditions
Conditions Yield
With hydroxylamine hydrochloride; potassium carbonate; In ethanol; at 20 ℃; for 7h; Reflux;
64%
With hydroxylamine hydrochloride; potassium carbonate; In ethanol; for 4h; Reflux;
60%
With hydroxylamine; In methanol; for 16h; Heating;
1.9 g
With potassium hydroxide; hydroxylamine hydrochloride; at 20 - 40 ℃; for 18h;
With hydroxylamine hydrochloride; triethylamine; In methanol; at 60 ℃; for 12h; Inert atmosphere;
4-Bromophenylacetonitrile
16532-79-9

4-Bromophenylacetonitrile

2-(4-bromophenyl)-N'-hydroxyacetimidamide
422560-40-5

2-(4-bromophenyl)-N'-hydroxyacetimidamide

Conditions
Conditions Yield
With hydroxylamine; In ethanol; water; at 80 ℃; for 16h; Inert atmosphere;
85%
With sodium hydroxide; hydroxylamine hydrochloride; In ethanol; for 48h; Heating;
With hydroxylamine hydrochloride; potassium hydroxide; In methanol; at 20 ℃; Alkaline conditions;
4-Bromophenylacetonitrile
16532-79-9

4-Bromophenylacetonitrile

2-(4-bromophenyl)-N-hydroxyacetamidine
422560-40-5

2-(4-bromophenyl)-N-hydroxyacetamidine

Conditions
Conditions Yield
With hydroxylamine hydrochloride; sodium hydrogencarbonate; In methanol; water; Reflux;
4-Bromophenylacetonitrile
16532-79-9

4-Bromophenylacetonitrile

hydroxylamine hydrochloride
5470-11-1

hydroxylamine hydrochloride

2-(4-bromophenyl)-1-(hydroxyimino)ethylamine
422560-40-5

2-(4-bromophenyl)-1-(hydroxyimino)ethylamine

Conditions
Conditions Yield
With sodium carbonate; In methanol; water;
4-Bromophenylacetonitrile
16532-79-9

4-Bromophenylacetonitrile

(z)-2-(4-bromophenyl)-N′-hydroxyacetimidamide
1433999-78-0,422560-40-5

(z)-2-(4-bromophenyl)-N′-hydroxyacetimidamide

Conditions
Conditions Yield
With hydroxylamine hydrochloride; potassium carbonate; In ethanol; at 20 ℃; for 7h; Reflux;
64%
With hydroxylamine hydrochloride; potassium carbonate; In ethanol; for 4h; Reflux;
60%
With hydroxylamine; In methanol; for 16h; Heating;
1.9 g
With potassium hydroxide; hydroxylamine hydrochloride; at 20 - 40 ℃; for 18h;
With hydroxylamine hydrochloride; triethylamine; In methanol; at 60 ℃; for 12h; Inert atmosphere;
4-Bromophenylacetonitrile
16532-79-9

4-Bromophenylacetonitrile

2-(4-bromophenyl)-N'-hydroxyacetimidamide
422560-40-5

2-(4-bromophenyl)-N'-hydroxyacetimidamide

Conditions
Conditions Yield
With hydroxylamine; In ethanol; water; at 80 ℃; for 16h; Inert atmosphere;
85%
With sodium hydroxide; hydroxylamine hydrochloride; In ethanol; for 48h; Heating;
With hydroxylamine hydrochloride; potassium hydroxide; In methanol; at 20 ℃; Alkaline conditions;
4-Bromophenylacetonitrile
16532-79-9

4-Bromophenylacetonitrile

2-(4-bromophenyl)-N-hydroxyacetamidine
422560-40-5

2-(4-bromophenyl)-N-hydroxyacetamidine

Conditions
Conditions Yield
With hydroxylamine hydrochloride; sodium hydrogencarbonate; In methanol; water; Reflux;
4-Bromophenylacetonitrile
16532-79-9

4-Bromophenylacetonitrile

hydroxylamine hydrochloride
5470-11-1

hydroxylamine hydrochloride

2-(4-bromophenyl)-1-(hydroxyimino)ethylamine
422560-40-5

2-(4-bromophenyl)-1-(hydroxyimino)ethylamine

Conditions
Conditions Yield
With sodium carbonate; In methanol; water;

Global suppliers and manufacturers

Global( 7) Suppliers
  • Company Name
  • Business Type
  • Contact Tel
  • Emails
  • Main Products
  • Country
  • Amadis Chemical Co., Ltd.
  • Business Type:Lab/Research institutions
  • Contact Tel:86-571-89925085
  • Emails:sales@amadischem.com
  • Main Products:29
  • Country:China (Mainland)
  • Finetech Industry Limited
  • Business Type:Trading Company
  • Contact Tel:86-27-87465837
  • Emails:sales@finetechnology-ind.com
  • Main Products:29
  • Country:China (Mainland)
  • Boc Sciences
  • Business Type:Trading Company
  • Contact Tel:1-631-485-4226
  • Emails:sales@bocsci.com
  • Main Products:41
  • Country:United States
close

Please post your buying leads,so that our qualified suppliers will soon contact you!

*Required Fields

CAS No.:
* Product Name:
* Your email:

Your email will be used to sign-in to LookChem.com
* Requirements:
* Valid for:
 
Post Buying Request Now
close
Remarks: The blank with*must be completed